Latest studies
- Active not recruitingPHASE3
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
This study looks at treating muscle-invasive bladder cancer. It compares standard chemotherapy with chemotherapy plus a new immunotherapy drug called nivolumab, given before and after surgery. The aim is to see if adding nivolumab helps more people.
Urinary Bladder NeoplasmsMuscle-Invasive Bladder CancerNew Zealand - RecruitingPHASE3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
This study, called REMAP-CAP, looks at different treatments for serious lung infections like pneumonia, flu, and COVID-19 in adults needing intensive care. It aims to find out which treatments work best to help patients recover.
Community-acquired Pneumonia, Influenza, COVID-19New Zealand - Active not recruitingPHASE3
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
This study looks at a new combination of medicines for postmenopausal women with a certain type of breast cancer. It tests if abemaciclib with standard hormone therapy works better than hormone therapy alone.
Breast CancerNew Zealand - RecruitingPHASE3
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
This study is looking into a new medication called AZD0780. It aims to see if this medicine can lower the risk of serious heart problems like heart attacks or strokes in people who have already had them, or in those at high risk of having one for the first time.
Cardiovascular DiseaseNew Zealand - Active not recruitingPHASE3
HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
This study is testing a new medicine, NTLA-2002, for people with Hereditary Angioedema (HAE). We want to see how well it works and if it's safe compared to a placebo (a dummy medicine) to reduce HAE attacks.
Hereditary AngioedemaNew Zealand - Recruiting
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
This study, HDClarity, aims to gather fluid samples from people with Huntington's disease to find better ways to treat it. By studying blood and spinal fluid, researchers hope to understand the disease better and develop new medicines.
Huntington's DiseaseNew Zealand - RecruitingPHASE3
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
This study is looking at a new drug, casdatifan, combined with an existing one, cabozantinib, for advanced clear cell kidney cancer. It compares this combination to cabozantinib with a dummy drug (placebo) to see if it stops cancer growth for longer in patients who've already had immunotherapy.
Metastatic Clear Cell Renal Cell CarcinomaAdvanced Clear Cell Renal Cell CarcinomaNew Zealand - Active not recruitingPHASE2
Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)
This study is testing a new medicine called sevasemten (also known as EDG-5506) for adults with Becker muscular dystrophy. It wants to see if the medicine is safe and if it helps people. Early parts of the study are now full, but one large part, GRAND CANYON, has also finished taking new participants.
Becker Muscular DystrophyNew Zealand - RecruitingPHASE1
A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
This study is testing a new gene-editing treatment called VERVE-102 for people with high cholesterol due to a genetic condition (Familial Hypercholesterolemia) or early heart disease. It aims to see if VERVE-102 is safe and can help lower 'bad' cholesterol.
Heterozygous Familial HypercholesterolemiaPremature Coronary Heart DiseaseNew Zealand - RecruitingPHASE3
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
This study compares new ways to treat advanced lung cancer. It looks at two drug combinations, Nivolumab and Relatlimab plus chemotherapy, versus Pembrolizumab plus chemotherapy. The goal is to find the best treatment for a specific type of lung cancer.
Non-small Cell Lung CancerNew Zealand - RecruitingPHASE3
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This study compares two medicines, BGB-16673 and pirtobrutinib, for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) when previous treatments haven't worked well enough. It aims to see which medicine is safer and more effective.
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaNew Zealand - Active not recruitingPHASE3
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
This study is testing a new medicine, tulisokibart, for people with moderate to severe ulcerative colitis. It aims to see if the medicine can help people feel better and stay in remission, compared to a dummy medicine, both in the short and long term.
Ulcerative ColitisNew Zealand - RecruitingPHASE3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
This study is testing a new medicine, lunsekimig, for people with COPD who still have symptoms even with current treatments. It aims to see if lunsekimig is safe and helps improve COPD, particularly for those with a specific type called an 'eosinophilic phenotype'.
Chronic Obstructive Pulmonary DiseaseNew Zealand - RecruitingPHASE1
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
This study is testing a new drug, zanzalintinib, alone and with other medicines, for people with advanced cancers like kidney, prostate, and lung cancer. It's looking at safety and if the treatment shrinks tumours.
Renal Cell Carcinoma (RCC)Metastatic Castration-Resistant Prostate Cancer (mCRPC)Urothelial Carcinoma (UC)Solid TumorNew Zealand - Active not recruitingPHASE3
Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)
This study looks at a new medicine called Seladelpar for Primary Biliary Cholangitis (PBC). It's a long-term study to see how safe and effective it is over time. Participants will have taken Seladelpar in a previous study.
Primary Biliary CirrhosisNew Zealand - Active not recruitingPHASE3
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
This study looks at a new drug, astegolimab, for people with COPD who have flare-ups often. It compares the new drug to a dummy treatment (placebo) to see if it's safe and helps improve their breathing and reduce flare-ups.
Chronic Obstructive Pulmonary Disease (COPD)New Zealand - RecruitingPHASE3
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
This study is looking at two new drug combinations for adults newly diagnosed with Chronic Lymphocytic Leukemia (CLL). It compares sonrotoclax plus zanubrutinib with venetoclax plus acalabrutinib to see which is more effective and safer for treating this type of blood cancer.
Chronic Lymphocytic LeukemiaNew Zealand - RecruitingPHASE2
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
This study is testing a new medicine, Vamifeport, for people with a common type of iron overload called hereditary hemochromatosis. It aims to see if the medicine can reduce the amount of iron stored in the liver. Two groups will be compared: one getting the medicine and one getting a dummy pill.
Homeostatic Iron Regulator Gene-related Hereditary HemochromatosisNew Zealand - Enrolling by invitation
Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular Disease
This study is following people who've had an experimental gene therapy for certain heart conditions. It checks how the treatment affects them over a long time, up to 15 years, looking for any lasting benefits or side effects to make sure it's safe and works well.
Atherosclerotic Cardiovascular DiseaseHeterozygous Familial HypercholesterolemiaHypercholesterolemiaNew Zealand - RecruitingNA
Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration
This study is looking at a new treatment called i-Lumen AMD, which uses a gentle electric current to help people with a common eye condition called Age-related Macular Degeneration (AMD). The aim is to see if it's safe and effective for slowing down the problem in the eyes.
Age-Related Macular DegenerationAge-related Macular Degeneration (ARMD)Intermediate AMDGeographic Atrophy Secondary to Age-related Macular DegenerationNew Zealand - RecruitingPHASE4
NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients
This study looks at how high doses of certain heart medicines (RAS-antagonists and beta-blockers) might help prevent heart problems in people with Type 2 diabetes who haven't had heart disease before. It also checks a blood marker called NT-proBNP.
Heart DiseasesDiabetes Mellitus, Type 2New Zealand - RecruitingPHASE1, PHASE2
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
This study is testing new treatments for advanced prostate cancer that has spread and no longer responds to hormone therapy. It aims to see how safe and effective a new drug, Opevesostat, is when given alone or with other medicines to men with this condition.
Prostatic Neoplasms, Castration-ResistantNew Zealand - Active not recruitingNA
The GORE® VIABAHN® FORTEGRA Venous Stent IVC Study
This study looks at a new stent, the GORE VIABAHN FORTEGRA, for problems with veins in the belly and legs. It aims to improve symptoms like swelling, pain, and ulcers caused by blockages in these important veins.
Venous ThrombosesVenous DiseaseVenous Leg UlcerVenous StasisNew Zealand - RecruitingPHASE1, PHASE2
A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1
This study is looking into a new medicine called ALE1 for a rare bone condition called Hypophosphatasia (HPP). It will first check if ALE1 is safe in healthy adults, then see how it works in adults with HPP. The aim is to find suitable doses.
Hypophosphatasia (HPP)New Zealand - Active not recruitingPHASE3
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
This study looks at a new medicine called survodutide for people who are overweight or obese. It checks if survodutide helps with heart health problems. Participants take the medicine weekly for up to 2 years, alongside diet and exercise advice.
ObesityNew Zealand - Recruiting
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
Enroll-HD is a long-term study collecting information and samples from people with or at risk of Huntington's disease (HD), and their families. This helps researchers worldwide better understand HD, find new ways to treat it, and design better clinical trials for the future.
Huntington's DiseaseNew Zealand - Active not recruitingPHASE1, PHASE2
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
This study looks at new drug combinations for advanced kidney cancer that has not responded to previous treatments. It aims to see how safe and effective these new combinations are.
Carcinoma, Renal CellNew Zealand - RecruitingPHASE3
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
This study is testing a new drug, daraxonrasib, for people with a specific type of advanced lung cancer (non-small cell lung cancer, or NSCLC) that has a RAS gene change. It compares the new drug to an existing chemotherapy, docetaxel, to see if it works better or has fewer side effects.
NSCLC (Non-small Cell Lung Cancer)Non-Small Cell Lung CancerNSCLCNSCLC (Non-small Cell Lung Carcinoma)New Zealand - RecruitingPHASE3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
This study is for people who have already taken part in other studies for a medicine called sotatercept, used to treat Pulmonary Arterial Hypertension (PAH). It aims to check the long-term safety and how well people tolerate sotatercept when taken with their usual PAH treatments.
Pulmonary Arterial HypertensionNew Zealand - Active not recruitingPHASE3
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
This study looks at a medicine called nivolumab for liver cancer. It's for people who've had surgery or other treatment to remove their cancer, but are at high risk of it coming back. We want to see if nivolumab can stop the cancer from returning.
Hepatocellular CarcinomaLiver CancerNew Zealand - Active not recruitingPHASE2
A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)
This study looks at a new drug, ALG-000184, for chronic hepatitis B. It compares it with an existing treatment, tenofovir, to see how safe and effective it is over 48 weeks. It's for adults who haven't been treated for hepatitis B before.
Chronic Hepatitis B InfectionNew Zealand - RecruitingPHASE1
A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease
This is a new study in the UK looking at a trial medicine called SRP-1005 for people with Huntington's disease. It's the very first time this medicine is being tested in humans to see if it's safe and how it affects the body in patients with Huntington's.
Huntington's DiseaseNew Zealand - RecruitingPHASE3
Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
This study is testing a new oral medication, LUM-201, for children with Growth Hormone Deficiency. We want to see if it helps children grow and how well our special test helps choose those who will benefit most from it.
Growth Hormone Deficiency (GHD)New Zealand - Active not recruitingPHASE2
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
This study is for people with advanced solid cancers that haven't responded to other treatments. It uses a "precision medicine" approach, matching treatments to the specific genetic changes found in each person's tumour, aiming for more effective and personalised care.
Solid TumorsNew Zealand - RecruitingPHASE3
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
This study compares two treatments, NXT007 and emicizumab, for people aged 12 and over with haemophilia A. It aims to see how well they prevent bleeding, if they are safe, and how they work in the body.
Hemophilia ANew Zealand - Active not recruitingPHASE3
Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line
This study is looking at a new treatment called dostarlimab for advanced or recurring endometrial cancer that has a specific genetic feature (MMR deficient). It compares dostarlimab with standard chemotherapy to see which works better and is safer for patients.
Endometrial CancerNew Zealand - Active not recruitingPHASE3
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
This study looks at a new drug, navitoclax, combined with ruxolitinib, or navitoclax alone, for adults with myelofibrosis whose previous treatment didn't work. It compares these to standard care to see how they affect spleen size and safety.
Myelofibrosis (MF)New Zealand - Enrolling by invitation
Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002
This study is checking on people who previously received a new treatment called NTLA-2002 for hereditary angioedema. It aims to see how they are doing in the long run and understand the lasting effects of the treatment over time.
Hereditary AngioedemaNew Zealand - Active not recruitingPHASE3
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
This study is looking at new ways to treat advanced kidney cancer that hasn't been treated before. It combines three medicines to see if they work better together than two, aiming to help people live longer and keep their cancer from growing.
Renal Cell CarcinomaNew Zealand - RecruitingPHASE3
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
This study is for people with early-stage Hodgkin Lymphoma. It compares two chemotherapy treatments, ABVD and A2VD, to see which works best. Treatment is adjusted based on scans, and patients are followed for at least 5 years.
Hodgkin LymphomaNew Zealand - Active not recruitingPHASE3
Olorofim Aspergillus Infection Study
This study compares a new medicine, olorofim, with an existing one, AmBisome®, for treating a serious fungal infection called invasive aspergillosis (IA). We want to see if olorofim is safe and effective, especially for patients who haven't responded well to other treatments.
Invasive AspergillosisNew Zealand - Active not recruitingNA
AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion
This study looks at a new treatment called IMPEDE-FX RapidFill for a swollen main artery in your tummy (abdominal aortic aneurysm). It aims to see if this treatment, used with a standard repair, can help shrink the swollen area and make it safer.
Aortic Aneurysm, AbdominalNew Zealand - RecruitingPHASE2, PHASE3
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
This study is looking at a new oral medicine, enlicitide decanoate, for children and teenagers aged 6-17 with a condition called Heterozygous Familial Hypercholesterolemia (HeFH). We want to see if it's safe and helps lower high cholesterol levels.
Heterozygous Familial Hypercholesterolemia (HeFH)New Zealand - Active not recruitingPHASE2, PHASE3
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
This study looks at a new drug, Inavolisib, combined with standard treatments (Palbociclib and Fulvestrant) for a specific type of advanced breast cancer. It compares this new combination to the standard treatments alone, checking how well it works and if it's safe.
Breast CancerNew Zealand - RecruitingPHASE3
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
This study is testing a new medicine, depemokimab, for adults aged 40-80 with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) and a specific type of inflammation. It aims to see if depemokimab improves symptoms and is safe when added to their usual inhaler treatment.
Pulmonary Disease, Chronic ObstructiveNew Zealand - RecruitingPHASE1, PHASE2
A Study of BGB-11417 in Participants With Myeloid Malignancies
This study is looking at a new drug, BGB-11417, for certain blood cancers like acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). Researchers want to see if it's safe, what dose works best, and if it helps people, either alone or with another treatment called azacitidine.
Acute Myeloid LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative NeoplasmNew Zealand - Recruiting
SCAD : a Registry of Spontaneous Coronary Artery Dissection
This study is gathering information on a heart condition called Spontaneous Coronary Artery Dissection (SCAD). It's looking at how doctors currently diagnose and treat SCAD across Europe to learn more about it and improve care for patients.
Spontaneous Coronary Artery DissectionNew Zealand - Active not recruitingPHASE3
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
This study looks at a new drug, cemiplimab, for people who have had surgery and radiotherapy for a serious form of skin cancer (squamous cell carcinoma). We want to see if cemiplimab can stop the cancer from coming back.
Cutaneous Squamous Cell CarcinomaNew Zealand - RecruitingPHASE4
Staphylococcus Aureus Network Adaptive Platform Trial
The SNAP trial is studying different treatments for a serious blood infection called Staphylococcus aureus (S. aureus) to find out which ones work best. It aims to reduce serious illness and death by testing various medicines and approaches.
Staphylococcus Aureus BacteremiaNew Zealand - Active not recruitingPHASE2
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
This study is for people with cancer that has spread, who are already benefiting from a specific medicine called trastuzumab emtansine (T-DM1) or other similar treatments in an earlier study. It allows them to keep receiving these important treatments for longer to see if they continue to help.
Neoplasm MetastasisNew Zealand